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In this issue of Blood, Catto et al1 describe for the first time the occurrence of
somatic genetic rescue (SGR) in an asymptomatic individual carrying a
pathogenic germline mutation in GATA2. The authors hypothesize that early
recovery of hematopoiesis may also have prevented extrahematological
features of GATA2 deficiency in this individual. The finding of SGR in GATA2
deficiency stresses once more that awareness for this phenomenon is needed
in genetic counseling and testing of pre- or asymptomatic individuals in
families with hereditary bone marrow failure.
GATA2 deficiency results from hetero-
zygous loss-of-function mutations in
the GATA2 gene, resulting in haplo-
insufficiency, and is characterized by
peripheral blood cytopenias of mono-
cytes, B lymphocytes and natural killer
cells, susceptibility to various infections,
and a high risk of developing hemato-
logic malignancies, mainlymyelodysplastic
syndrome and acute myeloid leukemia.
Other features are lymphedema, pulmo-
nary alveolar proteinosis, and hearing
loss.2 Catto et al report 2 brothers with
prominent features of GATA2 deficiency
who were shown to carry a nonsense
mutation inGATA2. In their asymptomatic
father, analysis of leukocyte DNA revealed
mosaicism for a silent missense mutation
at the exact same codon as the disease-
associated GATA2 mutation identified in
the sons, with extreme skewing toward the
silent mutation. SGR was restricted to the
blood lineage, as DNA from sperm and
skin fibroblasts still carried the GATA2
nonsense mutation.
With their report, the authors add to a
long list of Mendelian hematopoietic
diseases in which SGR has been de-
tected.3 SGR is caused by spontaneous
correction of a germline pathogenic al-
lele, which results in a selection advan-
tage and clonal expansion of cells lacking
the genetic aberration. This phenome-
non results in an improvement or even
prevention of the hematologic phenotype
caused by the germline pathogenic allele.3
In autosomal dominant hematologic dis-
orders associated with haploinsufficiency,
the most commonly observed mechanism
of SGR is mitotic recombination, resulting
in segmental uniparental disomy (UPD) of
the chromosome arm that carries the mu-
tated gene and thus replacement of the
mutated allele by an extra copy of the
wild-type allele. Other, much rarer mecha-
nisms include correction by a back mutation
or a compensatory mutation (see figure).1
The SGR mechanism described by Catto
and coworkers should be considered a
back mutation. Despite the involvement
of a second variant, as is observed in
compensatory mutations, the rescuing
mutation erases the pathogenic variant
and reverts the amino acid sequence to
wild type (see figure). SGR is one of
multiple explanations for variability in
phenotypic expression of an inherited
mutation. It can be easily overlooked since
not all events resulting in genetic rescue
are as eye-catching as the compensatory
variant described by Catto et al.
Nevertheless, it is still intriguing that this
is only the first report of SGR in GATA2
deficiency, whereas large case series of
patients with this syndrome have been
published.4,5 In hindsight, it may be
possible that one or more of the 6 pa-
tients with de novo mutations reported
by Donadieu et al are children of a parent
that experienced SGR.4
Several factors might influence the fre-
quency of SGR in a specific genetic
condition, and time is an important one.
In GATA2 deficiency, hematologic ma-
lignancies are a common first pre-
sentation of the disease, often at young
age,4 and a genetic rescue thus needs to
occur early in life, between conception
and malignant hematological clonal ex-
pansion. In conditions with a minor sus-
ceptibility to leukemia, like dyskeratosis
congenita, this timeframe is much larger,
creating more opportunity for SGR to
occur.6 In the patient described by Catto
et al, SGR was present in T cells, which
have a long lifespan. This observation
made the authors conclude that indeed
SGR occurred early in his life.
SGR is driven by a clonal advantage
of “rescued cells” above cells carrying
the germline mutation. Variability in
clonal advantage likely is another factor
influencing the frequency of SGR. In in-
dividuals with GATA2 deficiency, hema-
topoiesis in early childhood appears to
be grossly intact, and it has been sug-
gested that other genetic, epigenetic, or
environmental factors may contribute to
bone marrow failure in these patients.7
Possibly SGR can only become apparent
in this more severe stage of the disease.
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An additional factor of influence on SGR
frequency might be the location of the
gene relative to the telomeric end of
the chromosome. Mitotic recombination,
the most frequent event involved, requires
the breakpoint to be located centromeric
of the mutated gene. Consequently, the
more telomeric a gene is located and the
longer the chromosome arm, the larger
the chance that a mitotic recombination
with a break on the centromeric site of
the germline mutation will occur. Even
multiple events of mitotic recombina-
tion can be observed per patient.6,8 For
example, TERC, a gene causing dysker-
atosis congenita and described to un-
dergo SGR by mitotic recombination, is
located toward the telomere of chro-
mosome 3q, whereas GATA2 is located
much closer to the centromere of 3q.
Catto et al conclude that their finding
suggests that early recovery of hemato-
poiesis in GATA2 deficiency either by
transplant or potentially by gene therapy
may be beneficial for hematopoiesis and
to prevent other clinical complications.
Previous studies have indeed observed a
trend that the earlier hematopoietic stem
cell transplantation is performed in pa-
tients with GATA2 deficiency, the better
the outcome.4,9 With the promising de-
velopment of gene-repair technologies
implementing CRISPR/CAS, it is imagin-
able that patients with hematological
conditions amenable for SGR will be no
longer dependent on fate for a rescue to
occur, but can actively be helped.
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Mutated cells cause bone
marrow failure syndrome
Somatic genetic rescue Clonal expansion of
reverted cells
Consequences
•  Milder or no disease phenotype
•  May result in false-negative








•  Selection advantage of
    nonmutant over mutant cells
•  Typical for diseases affecting
    regenerating organ systems
Prerequisites Rescue events
Schematic presentation of SGR in conditions caused by autosomal dominant haploinsufficient genetic variants. Four causative mechanisms for these conditions have been
described (Rescue events), either by making use of the functional wild-type allele (reversion by mitotic recombination resulting in segmental UPD, or promoter activation) or by
correcting functionality of the mutated copy through a compensatingmutation or a back mutation. A compensatingmutation (blue dot) occurs on a different location within the
same gene copy and takes away the deleterious effect of the pathogenic mutation (green dot), for example, by restoring the reading frame of a pathogenic frameshift mutation.
A back mutation reverts the original mutation back to normal. The GATA2 rescue event described by Catto and coworkers is of the “back mutation” type, where in the
pathogenic germline GATA2 c.216C.A (p.Y72*) variant, the A residue is spontaneously remutated into a T, by which the amino acid sequence is restored (c.216C.T; p.Y72Y).
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